Clinical trial
PPI Sequencing Study
NCT00384592 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00384592 |
|---|---|
| Title | PPI Sequencing Study |
| Official title | A Study to Assess the Effectiveness of Esomeprazole 40 mg Once Daily in Subjects With Continuing Gastroesophageal Reflux Disease (GORD) Symptoms Following Treatment Wit a Previous Full Dose Proton Pump Inhibitor (PPI) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Gastro-Oesophageal Reflux Disease |
| Intervention type | Drug, Procedure |
| Interventions | Esomeprazole, Physical exam, Pregnancy test if applicable |
| Enrollment | 100 |
| Start date | Sep 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Oct 6, 2006 |
| Last update posted | Mar 11, 2009 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: